Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists

Hongliang Duan, Mengmeng Ning, Xiaoyan Chen, Qingan Zou, Liming Zhang, Ying Feng, Lina Zhang, Ying Leng, Jianhua Shen

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)

Abstract

4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC 50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)0-120min following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.

Original languageEnglish
Pages (from-to)10475-10489
Number of pages15
JournalJournal of Medicinal Chemistry
Volume55
Issue number23
DOIs
Publication statusPublished - 13 Dec 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists'. Together they form a unique fingerprint.

Cite this